EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A

Ming Y Lim, Kristy Lee, Jill M Johnsen iD, Nigel S Key iD

Haemophilia · 2025

DOI: 10.1111/hae.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Ming Y Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hemostasis and Thrombosis Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neutralising antibodies (inhibitors) against factor VIII can result in severe bleeding in persons with nonsevere haemophilia A (NSHA). The INSIGHT study of 1112 persons with NSHA in a predominantly White population identified 19 different F8 missense variants that were associated with inhibitor development.

Objective

To describe the F8 variants and inhibitor development in persons with NSHA in a multiethnic cohort using the My Life, Our Future (MLOF) Research Repository and the American Thrombosis and Hemostasis Network dataset (ATHNdataset).

Methods

The MLOF Research Repository and ATHNdataset were queried for demographic, clinical and genotyping data.

Results

A total of 1805 persons with NSHA with at least one reportable F8 variant and known inhibitor status were included in this study. Inhibitors were developed in 142 (7.9%) persons with NSHA. Inhibitor development occurred in seventy F8 variants, of which the majority ( n = 67, 95.7%) were missense variants. These 70 F8 variants were identified in a total of 1006 (55.7%) persons with NSHA. Race or ethnicity was not associated with inhibitors in persons with NSHA.

Conclusion

The MLOF Research Repository identified additional F8 variants where inhibitor development occurred in a multiethnic cohort of NSHA. Identification of these F8 variants can inform both physicians and persons with NSHA to adopt measures to reduce the risk of inhibitor development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansMaleAdultCohort StudiesMiddle AgedAdolescentChildEthnicityFemaleYoung AdultMutation, MissenseChild, PreschoolAged

Stichwörter der Autor:innen

ethnicitygenotypehaemophilia Aracial groupsrisk

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, Salt Lake City, Utah, USA.
  • Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Institute For Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Division of Hematology and Blood Research Center, University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Jill M Johnsen, Nigel S Key

Förderung

  • Hemostasis and Thrombosis Research Society

Zitieren

APA

Lim, M. Y., Lee, K., Johnsen, J. M., & Key, N. S. (2025). F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.70143

Vancouver

Lim MY, Lee K, Johnsen JM, Key NS. F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.70143

BibTeX
@article{Lim2025,
  author = {Lim, Ming Y and Lee, Kristy and Johnsen, Jill M and Key, Nigel S},
  title = {F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70143}
}
Kostenlos starten →